July 7, 2022
Life Sciences
  • Senate Democrats narrowly reached a deal on drug pricing reforms, which includes granting Medicare the power to negotiate prices for certain drugs. According to text released Wednesday, the U.S. Department of Health and Human Services (HHS) will choose 10 drugs eligible for negotiation in 2026, 15 eligible drugs in 2027, and 20 eligible drugs yearly starting in 2029. The deal also repeals the controversial Part D rebate rule and installs a cap on monthly cost-sharing payments for Part D and Medicare Advantage plans. (Articles here, here, here, here, here, here, and here)